NPR logo

Cancer News

  • Download
  • <iframe src="https://www.npr.org/player/embed/1687468/1687469" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
Cancer News

Cancer News

Cancer News

  • Download
  • <iframe src="https://www.npr.org/player/embed/1687468/1687469" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

Last week the FDA approved Erbitux (ERB-ih-tux) a so-called "targeted cancer therapy" that could help people in the late stages of colon cancer. Erbitux is the latest addition to a relatively new class of cancer-fighting drugs called monoclonal antibodies. In this hour, we'll take a look at these, and other new cancer drugs. How are they changing the way we fight cancer? We'll also take a look at the link between chronic antibiotic use and breast cancer.

Guests:

Dr. Larry Norton
*Deputy physician in chief for breast cancer programs at the *Memorial Sloan Kettering Cancer Center in New York

Dr. Brian Druker
*Associate professor, medicine (hematology and medical oncology), biochemistry and molecular biology, and cell and developmental biology at the Oregon Health Science University, School of Medicine
*Leader, Oregon Cancer Center Hematologic Malignancies Program in Portland, Ore.